A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms PROLONG
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 03 Mar 2018 The study has been discontinued in Finland.
- 02 Mar 2018 The study has been discontinued in Spain.
- 16 Feb 2018 This study has been discontinued in Hungary as per European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History